| Literature DB >> 32326348 |
Wantida Chaiyana1,2, Sunee Chansakaow1, Nutjeera Intasai3, Kanokwan Kiattisin1,2, Kuan-Han Lee4, Wei-Chao Lin5, Shang-Chian Lue5, Pimporn Leelapornpisid1,2.
Abstract
This study aimed to investigate the potential usage of Thunbergia laurifolia Lindl. leaf extracts in the cosmetic industry. Matrix metalloproteinases (MMPs) and hyaluronidase inhibition of T. laurifolia leaf extracts, prepared using reflux extraction with deionized water (RE) and 80% v/v ethanol using Soxhlet's apparatus (SE), were determined. Rosmarinic acid, phenolics, and flavonoids contents were determined using high-performance liquid chromatography, Folin-Ciocalteu, and aluminum chloride colorimetric assays, respectively. Antioxidant activities were determined by 1,1-diphenyl-2-picrylhydrazyl (DPPH) and linoleic acid-thiocyanate assays. MMP-1 inhibition was investigated using enzymatic and fluorescent reactions, whereas MMP-2, MMP-9, and hyaluronidase inhibition were investigated using gel electrophoresis. Cytotoxicity on human fibroblast cell line was also investigated. The results demonstrated that SE contained significantly higher content of rosmarinic acid (5.62% ± 0.01%) and flavonoids (417 ± 25 mg of quercetin/g of extract) but RE contained a significantly higher phenolics content (181 ± 1 mg of gallic acid/g of extract; p < 0.001). SE possessed higher lipid peroxidation inhibition but less DPPH• scavenging activity than RE. Both extracts possessed comparable hyaluronidase inhibition. SE was as potent an MMP-1 inhibitor as gallic acid (half maximal inhibitory concentration values were 12.0 ± 0.3 and 8.9 ± 0.4 mg/cm3, respectively). SE showed significantly higher MMP-2 and MMP-9 inhibition than RE (p < 0.05). Therefore, SE is a promising natural anti-ageing ingredient rich in rosmarinic acid and flavonoids with antioxidant, anti-hyaluronidase, and potent MMPs inhibitory effects that could be applied in the cosmetic industry.Entities:
Keywords: Thunbergia laurifolia; antioxidant; cytotoxicity; hyaluronidase; matrix metalloproteinases; rosmarinic acid
Year: 2020 PMID: 32326348 PMCID: PMC7221723 DOI: 10.3390/molecules25081923
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1HPLC chromatograms of (a) T. laurifolia leaf extracts prepared using Soxhlet’s apparatus with 80% v/v ethanol (SE), (b) T. laurifolia leaf extracts prepared using reflux extraction with deionized water (RE), and (c) rosmarinic acid detected at the wavelength of 280 nm; (d) SE, (e) RE, and (f) rosmarinic acid detected at 320 nm.
Total phenolics and total flavonoids content of Thunbergia laurifolia leaf extracts.
| Sample | Total Phenolic Content | Total Flavonoids Content |
|---|---|---|
| SE 1 | 174 ± 2 | 417 ± 25 *** |
| RE 2 | 181 ± 1 ** | 270 ± 10 |
1 SE, T. laurifolia extracted by Soxlet apparatus; 2 RE, T. laurifolia extracted by reflux. Asterisks denotes significantly different between SE and RE; * p < 0.01, *** p < 0.001.
Antioxidant activity of T. laurifolia leaf extracts.
| Sample | Half Maximal Inhibitory Concentration (IC50: μg/cm3) | |
|---|---|---|
| 1,1-diphenyl-2-picrylhydrazyl (DPPH Inhibition) | Lipid Peroxidation Inhibition | |
| Ascorbic acid | 4.4 ± 0.3 b | N.D. |
| α-Tocopherol | N.D. | 4.3 ± 0.3 c |
| Trolox | 6.8 ± 0.6 c | 0.2 ± 0.0 a |
| Gallic acid | 1.8 ± 0.0 a | 1.2 ± 0.1 b |
| Quercetin | 2.7 ± 0.5 a,b | 0.1 ± 0.0 a |
| SE | 217 ± 8 e | 8 ± 1 d |
| RE | 89 ± 1 d | 12.9 ± 0.1 e |
N.D., not determined. a, b, c, d, and e denote significantly different among samples at p < 0.05.
Figure 2Dose response curve against matrix metallopeptidase-1 (MMP-1) of gallic acid (GA), T. laurifolia leaves extracted by Soxlet apparatus (SE), and T. laurifolia extracted by reflux extraction (RE).
Figure 3MMP-2 and -9 inhibitory activities of T. laurifolia leaves extracted by Soxlet apparatus (SE) and reflux extraction (RE). Asterisks denotes significant differences between SE and RE; *** p < 0.001.
Figure 4Hyaluronidase (HAase) inhibitory activities of T. laurifolia leaves extracted by Soxlet apparatus (SE) and reflux extraction (RE).
Figure 5Human fibroblast BJ cell viability after treated with (a) SE and (b) RE.